[1]Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer [J]. Annu Rev Med, 2015, 66: 161-176.
[2]Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment [J]. Curr Cardiol Rev, 2011, 7(4): 214-220.
[3]Kim SY, Kim SJ, Kim BJ, et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes [J]. Exp Mol Med, 2006, 38(5): 535-545.
[4]Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity [J]. Nat Med, 2012, 18(11): 1639-1642.
[5]Tanaka A, Yuasa S, Node K, et al. Cardiovascular disease modeling using patient-specific induced pluripotent stem cells [J]. Int J Mol Sci, 2015, 16(8): 18894-18922.
[6]Karakikes I, Ameen M, Termglinchan V, et al. Human induced pluripotent stem cell-derived cardiomyocytes insights into molecular, cellular, and functional phenotypes [J]. Circ Res, 2015, 117(1): 80-88.
[7]Tsang WP, Chau SP, Kong SK, et al. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis [J]. Life Sci, 2003, 73(16): 2047-2058.
[8]Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced dna damage mediated by mammalian DNA topoisomerase-Ii [J]. Science, 1984, 226(4673): 466-468.
[9]Hensley ML, Hagerty KL, Kewalramani T, et al. American society of clinical oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants [J]. J Clin Oncol, 2009, 27(1): 127-145.
[10]Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer [J]. J Clin Oncol, 1997, 15(4): 1318-1332.
[11]Jirkovska-Ⅴavrova A, Jirkovsky E, Stariat J, et al. Anthracycline cardiotoxicity: The pharmacokinetics and pharmacodynamics of dexrazoxane and its putatively cardioprotective metabolite ADR-925 [J]. J Mol Cell Cardiol, 2014, 74: S22.
[12]Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase Ⅱ beta-Mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane [J]. Cancer Res, 2007, 67(18): 8839-8846.
[13]Scuderi GJ, Butcher J. Naturally engineered maturation of cardiomyocytes [J]. Front Cell Dev Biol, 2017, 5: 50.
[14]Veerman CC, Kosmidis G, Mummery CL, et al. Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? [J]. Stem Cells Dev, 2015, 24(9): 1035-1052.
[15]Talkhabi M, Aghdami N, Baharvand H. Human cardiomyocyte generation from pluripotent stem cells: A state-of-art [J]. Life Sci, 2016, 145: 98-113.
|